Oxford AstraZeneca

Revealed: Why the Oxford AstraZeneca Jab is Even More Dangerous than the mRNA ‘Vaccines’

People are dying and suffering from serious illness, including strokes, brain haemorrhages, blood clotting, blindness, heart attacks, neurological/nervous disorders, etc. soon after getting jabbed with any of the ‘vaccines’ currently available in the UK – Pfizer, Moderna and Oxford/AstraZeneca. This is a fact. 44 year old BBC presenter Lisa Shaw has just died from a blood clot, having been injected with AZ’s viral vector ‘vaccine’ – as part of a scandalously coerced mass vaccination program, in violation of the Nuremberg Code, fully supported by and sold to a gullible, fearful public by her own employer. The AZ jab definitely appears to be – at present – the worst offender as far as serious adverse reactions are concerned.

Our government, the media, the NHS and the MHRA tell us that this carnage means the AZ jab is ‘safe and rigorously tested’. 182,751 people, including 806 dead people, might disagree. Let us also be aware that many adverse reactions are not being reported, and indeed there is evidence to suggest that doctors and medical staff are deliberately not reporting adverse reactions to the jabs in those people they coerced to get jabbed. The VAERS database in the US for instance, is cited as recording only 1-10% of all adverse drug reactions.

Considering that many of the victims of this mass stabbing exercise by the state are people who are at minimal risk from Covid, considering that many of them will have already had robust and durable natural immunity to Covid anyway, via past infection, this is a massive scandal and evidence of an ongoing crime against humanity.

We now have emerging research which might explain why the adenovirus vectored Oxford AZ DNA jab is even more dangerous than the mRNA Pfizer and Moderna jabs. It has to do with the genetically modified chimpanzee adenovirus itself and the way in which it gets its ‘payload’ of SARS-Cov-2 spike encoding DNA into our cells.

During the last months many countries have started the immunization of millions of people by using
vector-based vaccines. Unfortunately, severe side effects became overt during these vaccination
campaigns: cerebral venous sinus thromboses (CVST), absolutely rare under normal life conditions, were
found as a severe side effect that occured 4-14 days after first vaccinations. Besides CVST, Splanchnic
Vein Thrombosis (SVT) was also observed. This type of adverse event has not been observed in the
clinical studies of AstraZeneca, and therefore led immediately to a halt in vaccinations in several
european countries. These events were mostly associated with thrombocytopenia, and thus, similar to the
well-known Heparin-induced thrombo cytopenia (HIT). Meanwhile, scientists have proposed a mechanism
to explain this vaccine-induced thrombocytopenia. However, they do not provide a satisfactory
explanation for the late thromboembolic events. Here, we present data that may explain these severe side
effects which have been attributed to adenoviral vaccines.

What is the fundamental difference between mRNA and vector-based vaccines? The mRNA vaccines are
delivered by a lipid nanoparticle containing the appropriate mRNA molecule – coding for the spike protein
of SARS-CoV-2 – to muscle cells surrounding the injection site. Cells that have successfully taken up these
nanoparticles will release their cargo mRNA into the cytosol, where it will be translated into Spike protein
in the rough endoplasmatic reticulum (ER). Subsequently, the translated and folded Spike proteins will be
post-translationally modified in the ER and Golgi apparatus and transported to the outer membrane – as
membrane-anchored proteins. This way, the immune system is able to recognize the viral antigen, which
in turn triggers the initial events for all subsequent immunological processes to produce specific B- and T effector cells.
What happens to the same Spike gene when delivered via an adenoviral system? The adenovirus life
cycle includes the infection of cells, uncoating of the virus in the cytosol, entry of the adenoviral DNA into
the nucleus, and subsequently gene transcription by the host transcription machinery (6). All adenoviral
systems follow exactly these steps (Ad5, Ad26 and chimp Ad). Thus, the SARS-CoV-2 Spike gene will be
transcribed inside of the nucleus and subsequently exported as mRNA out of the nucleus. Arriving in the
cytosol, the mRNA will again be translated into the Spike protein (see above).
And exactly here lies the problem: the viral piece of DNA – deriving from an RNA virus – is not optimized to
be transcribed inside of the nucleus. Solely this 3,822 nucleotide long open reading frame, coding for a
primary product of 1274 amino acid long Spike protein, contains 6 predicted splice donor and 5 predicted
acceptor sites. This problem becomes even more severe when using codon-optimized Spike reading
frames (depending on the company: up to 13 splice donor and 11 acceptor sites; see Fig. 1A). Thus, it
could well be that the Spike open reading frame of SARS-CoV-2 is potentially disrupted by arbitrary splice
events when transcribed inside the nucleus. Most, if not all, of these undesirable splice events would
produce shorter protein variants, disrupting the Spike protein upstream of the C-terminally located
membrane anchor, and thus, leading to soluble Spike protein variants.

In simple translation, what the authors are saying here is that because the AZ and other ‘vaccines’ deliver a piece of DNA (not mRNA) directly into the cell nucleus via the adenovirus vector, then there is the possibility that errors will occur when that DNA is transcribed back into RNA inside the nucleus. Thus, when the RNA is expelled from the nucleus into the surrounding cell material and starts instructing the cell machinery to manufacture the SARS-CoV-2 spike protein, those spike proteins produced might be ‘missing bits’; they will be shorter versions of the actual spike protein which, as result, will be able to migrate into the blood vessels where they will bind to platelets and cause serious health issues, namely haemorrhaging and clotting, which is exactly what we are seeing with AZ adverse reactions.

It’s not just the AZ ‘vaccine’:

The authors give the mRNA ‘vaccines’ a free pass on safety because they say that this production of soluble spike proteins just can’t happen with mRNA delivered into the cell cytosol:

Here, we present first molecular evidence that vector-based vaccines encoding the Spike protein exhibit a
problem that is completely absent in mRNA-based vaccines. This is due to the fact that during the
vaccination step, the adenoviral DNA enters the nucleus and use the host machinery to transcribe its
(trans)genes inside the nucleus. However, RNA viruses have evolved in the absence of any post transcriptional modifcation systems that are usually enabled to process the primary RNA transcripts of
nuclear encoded genes.

They even say the AZ ‘vaccine’ can be ‘re-optimized’:

Based on our findings, we strongly suggest that the Spike open reading frames – wildtype or codonoptimized in vector-based vaccines has to be re-optimized to avoid unintended splice reactions and to increase the safety of these pharmaceutical products. Vice versa, all mRNA-based vaccines should represent safe products, because the delivered mRNA will only be translated into surface antigen, without having any possibility to participate in nuclear splice events.

Unfortunately, spike proteins ‘leaking’ into the blood system can and do happen with other type ‘vaccines’ also, so it’s not a problem unique to AstraZeneca. The mRNA ‘vaccines’, though apparently less dangerous than the Oxford AZ viral vector vaccine, still have a whole host of serious side effects including thrombotic events like clots, strokes, heart attacks, haemorrhages, many linked to thrombocytopenia (low blood platelet count). Something which the manufacturers said couldn’t happen, has happened: spike proteins have been detected circulating in the blood of several volunteers who were administered the Moderna ‘vaccine’. Supposedly, they are at such minute concentrations that they cannot cause damage, but then this underpowered study looked at just a handful of healthy volunteers who were not suffering serious adverse side effects. The point is, the ‘experts’ have no explanation as to why they are there at all.

SARS-CoV-2 proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. 11 of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day one after first vaccine injection.

Nonetheless, evidence of systemic detection of spike and S1 protein production from the mRNA-1273 vaccine is significant and has not yet been described in any vaccine study, likely due to limitations in assay sensitivity and timing assessment. The clinical relevance of this finding is unknown and should be further explored.

It’s not just soluble SARS-CoV-2 spike proteins

The Daily Fail would have us believe that the problem with the AZ ‘vaccine’, which is just ‘very rare’ brain haemorrhages, has now been identified and can be fixed. Not really a big deal according to them.

Germans scientists say they have figured out why the Covid vaccines from  AstraZeneca and Johnson & Johnson are linked to rare blood clots

In a new pre-print, the team says the problem is with the adenovirus vector, a common cold virus used to get the body to induce an immune response

They claim the vaccine is sent into the cell nucleus instead of surrounding fluid, where parts of it break off and create mutated versions of themselves 

The mutated versions then enter the body and trigger the rare blood clots

Scientists say they can genetically adapt the vaccine to prevent the virus’s spike proteins, which it uses to enter cells, from splitting apart

That’s all OK then. What they don’t tell you, probably because they didn’t read the study carefully, assuming they even read it at all, is that this newly identified faulty transcription of DNA to RNA, resulting in the production of truncated, soluble spike proteins, is not the only problem with the viral vector ‘vaccines’. The other major problem is the genetically modified adenovirus vector itself. It too can bind to platelets and cause thrombocytopenia. The issue has been known about for at least 15 years, so there’s no excuse for the manufacturers to claim that such an adverse effect was unforeseen – it wasn’t. Here for instance:

Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors. The mechanism underlying this phenomenon is currently unknown.

And here:

Thrombocytopenia is a major adverse effect of high dose systemic administration of adenoviral (Ad) gene therapy vectors. While a previous report did not find platelet activation by Ad [1], recent studies have shown that Ad may activate platelets [2] and binds in vivo to murine thrombocytes resulting in hepatic sequestration [3]. Ad-induced thrombocytopenia has been shown to be dose-dependent, saturable and reversible [4], compatible with a ligand-receptor mechanism. Recently, binding of Ad to platelet was indirectly suggested following interference of platelet adhesion to fibronectin after incubation with Ad [2]. In this study we developed a direct flow cytometry assay to quantitatively analyze Ad attachment to human platelets in vitro and to characterize their interaction.

What this clearly tells us is that there are two major problems with the AZ viral vector vaccine, giving rise to very similar serious thrombotic adverse reactions associated with a low blood platelet count and those two problems arise separately as a result of SARS-CoV-2 spike proteins migrating into the blood, plus the adenovirus itself binding to blood platelets. The authors of this new study do actually point this out, but then they appear to ignore it, along with the media reporting on the paper.

Therefore, we propose a pathological disease mechanism that is depicted in Fig. 1D. On one hand, the
recently described VITT mechanism
is based on the artificial activation of PF4 by adenoviral proteins or
DNA molecules, which can similarly to heparin, act as a poly-anion to mediate PF4 activation. In patients
that exhibit a high load of auto-antibodies against PF4, this may cause the observed thrombocytopenia
(Fig. 1D, left side). The other side of the pathological disease mechanism is depicted as well (Fig. 1D, right
side). Based on our splicing data, membrane-anchored and soluble Spike protein variants are produced
after the vaccination procedure. When the immune system now starts the production of anti-Spike
antibodies (days 4–16), these antibodies will recognize the membrane-anchored as well as soluble Spike
proteins.

VITT is Vaccine Induced Thrombosis and Thrombocytopenia and is a known adverse effect of adenovirus gene therapy vectors, not just ‘vaccines’. Drug companies have known about the dangers for years. Here is the handy diagram provided by the authors of the new study, which distinguishes between the two:

In summary, the AZ ‘vaccine’ is dangerous; (a) as a result of a known side effect of the administration of adenovirus vectors, (b) as a result of an unforeseen faulty transcription of DNA into RNA, resulting in the production of soluble spike proteins, which are binding to blood platelets. The mRNA vaccines appear not to be so dangerous, but they certainly don’t have a free pass on safety, as implied wrongly by the authors of the new study on AZ adverse reactions.